SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MEDX ... anybody following?
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Icebrg7/26/2005 7:53:46 AM
  Read Replies (1) of 2240
 
PharmAthene has a good shot at landing the next BioShield contract, which the government is expected to award at the end of this year or in 2006. The company is working with Medarex on Valortim, and it plans to start human clinical trials this year. Animal trials show that Valortim provides protection when given before or up to 48 hours after exposure, says Mr. Wright.

redherring.com

Valortim is known in the Medarex Universe as MDX-1303. The news here is that PharmAthene is hoping to get the product into the clinic already this year. For som background on the Medarex/PharmAthene agreement.

Under the terms of the agreement, Medarex and PharmAthene have agreed to jointly continue to investigate the potential for MDX-1303 to be used as a therapeutic for individuals with active disease as well as for prophylactic treatment of individuals exposed to anthrax. Medarex will receive an initial payment from PharmAthene which will be used to fund development activities already underway for MDX-1303. PharmAthene will be fully responsible for funding all future research and development activities that are not supported by government funds. The companies will share profits according to a pre- agreed allocation percentage. The specific financial terms of the agreement have not been disclosed.

medarex.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News